Introduction {#Sec1}
============

Acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the Western world. Despite the use of percutaneous coronary intervention (PCI) for acute management of ACS, patients are still at risk for recurrent cardiovascular events \[[@CR1], [@CR2]\]. In this regard, antiplatelet agents, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB), β-blockers, and lipid-lowering agents are individually effective in reducing secondary cardiovascular events, and even more effective when combined together \[[@CR2]\].

The guidelines of the European Society of Cardiology on the management of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) \[[@CR3]\] and ST-segment elevation myocardial infarction (STEMI) \[[@CR4], [@CR5]\], as well as the American College of Cardiology/American Heart Association guidelines recommend the collective use of these pharmacological agents for long-term treatment of patients after ACS \[[@CR6]\]. Moreover, the prescription of these classes of agents at discharge is used as performance measures for patients with both ST-segment elevation and non-ST-segment elevation myocardial infarction \[[@CR3], [@CR7]\]. Nevertheless, there is evidence to suggest that patients with ACS are still not optimally managed with the aforementioned combination of agents after an acute coronary event \[[@CR8]\].

Accordingly, the purpose of the current study was to determine the individual and collective prescription rates of the 5 key guideline-recommended therapies (aspirin, thienopyridines, ACE-I/ARBs, β-blockers, and statins) after hospital discharge and adherence at 1-month follow-up in the first subset of 1000 ACS patients from the ongoing Rijnmond Collective Cardiology Research (CCR) registry. At the same time, this will serve as a baseline measurement for discharge management of ACS in our region, an important performance indicator of quality of care. We also sought to evaluate patient and practice characteristics associated with the collective use of these agents.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

Full details of the CCR study (*Dutch Trial Register* unique identifier: NTR3704) rationale and methodology are reported in the present issue of the *Netherlands Heart Journal* \[[@CR9]\] along with the current report. In brief, the CCR study is a prospective, multicentre, observational registry of management practices and outcome of ACS up to 12 months post-discharge. Eligible patients are (1) ≥18 years of age on presentation; (2) diagnosed with NSTE-ACS or STEMI and treated with PCI during index hospitalisation. The only exclusion criterion is intolerance for aspirin, clopidogrel or prasugrel. Currently, 11 member sites of the CCR network in the Rotterdam-Rijnmond region in the Netherlands ([Appendix](#Sec10){ref-type="sec"}) are participating in this observational study. Enrolment will continue until the intended number of 4000 patients is recruited. The CCR registry was initiated after updating treatment guidelines of the participating network to include prasugrel as the first-line treatment option for antiplatelet therapy.

Patient characteristics, clinical features, angiographic and procedural details, and in-hospital outcomes were abstracted from the medical chart per routine and entered into a secure web-based and centralised database by enrolling site personnel. After the index hospitalisation, patients were routinely followed up at 1 month and 12 months at the outpatient clinics of the enrolling sites, after which information on medication use and clinical outcomes was collected and entered into the central database. In the current study, continued adherence was assessed by patient report as provided during the 1-month follow-up visit.

The current study cohort was restricted to the first consecutive 1000 ACS patients enrolled in the CCR study who were alive at 1-month follow-up with complete follow-up data on discharge medications. These patients were recruited between August 2011 and February 2012.

Pharmacotherapy {#Sec4}
---------------

The 5 key guideline-recommended therapies of interest were aspirin, thienopyridines, ACE-I/ARBs, β-blockers, and statins. For the purpose of the present analysis, patients were divided into two subsets: those receiving all 5 pharmacological agents at discharge versus patients not receiving the 5-drug combination.

Ethics {#Sec5}
------

Patients were not subjected to acts or imposed to any mode of behaviour for the purpose of this study, other than standard treatment. Therefore, according to Dutch law, written informed consent for a patient to be enrolled in this study was not required. All patients provided oral assurance of their willingness to participate in the current study. This study is conducted according to the Privacy Policy of the Erasmus MC and according to the Erasmus MC regulations for the appropriate use of data in patient-oriented research, and is approved by the regional ethics committee (reference \# MEC-2010-417).

Statistical analysis {#Sec6}
--------------------

Continuous variables are summarised as mean ± standard deviation (SD) or median with interquartile range (IQR), depending on normal distribution and were compared using the Student *t*-test or Mann--Whitney *U*-test as appropriate. Categorical variables are summarised as percentages and were compared using the chi-square test. The McNemar test was used for pairwise comparisons of discharge and follow-up medication use. The primary study outcome was the collective discharge prescription of aspirin, thienopyridines, ACE-I/ARBs, β-blockers, and statins. Multivariable logistic regression was performed to identify patient and hospital characteristics independently associated with the collective use of the aforementioned 5 evidence-based agents using the forward selection method. The following candidate variables associated with the 5-drug combination therapy at discharge on univariate analyses (*p* \< 0.05) were entered into the model: age, diabetes, hypertension, hypercholesterolaemia, family history of coronary artery disease, previous coronary artery bypass grafting (CABG), enrolment into the registry at the interventional centre, unstable angina (UA), and STEMI. Model discrimination was evaluated by the c-statistic and calibration by the Hosmer-Lemeshow goodness-of-fit test.

All analyses were performed using SPSS version 20 (SPSS, Inc., Chicago, Illinois, USA) and two-tailed *P*-values \< 0.05 were considered to indicate statistical significance.

Results {#Sec7}
=======

The baseline characteristics of the study cohort are presented in Table [1](#Tab1){ref-type="table"}. The mean age was 63.7 ± 12.5 years, and 72.2 % were men. The most commonly documented comorbidities or risk factors present at the time of admission for the index ACS event included hypertension, family history of coronary artery disease, and smoking. Approximately 42 % presented with STEMI, 31 % with non-ST-segment elevation myocardial infarction, and 27 % with UA. A total of 652 ACS patients (65 %) received all 5 guideline-recommended classes of pharmacological agents at discharge. These patients were younger, more likely to have diabetes, hypertension, hypercholesterolaemia, and a family history of coronary artery disease, and more likely to be diagnosed with STEMI and enrolled to the registry in an interventional centre. In contrast, patients receiving the collective prescription of aforementioned agents were less likely to have previous CABG and less likely to be diagnosed with UA.Table 1Baseline demographic and clinical characteristicsCharacteristicsAll patients (*N* = 1000)Patients receiving 5-drug combination therapy^a^ at discharge (*N* = 652)Patients not receiving 5-drug combination therapy^a^ at discharge (*N* = 348)*P*Age, mean (SD)63.7 (12.5)62.6 (12.5)65.9 (12.3)\<0.001Male gender (%)72.272.870.90.53Risk factors (%) - Diabetes18.320.114.60.04 - Hypertension50.154.940.6\<0.001 - Hypercholesterolaemia36.440.229.40.001 - Current smoker37.238.237.50.86 - Family history45.650.642.70.02Medical history (%) - Previous MI19.119.618.20.59 - Previous HF3.93.45.10.20 - Previous CABG5.54.57.60.05 - Previous PCI19.619.919.00.76 - Previous stroke/TIA7.07.07.00.97Enrolment in interventional centre (%)42.046.232.9\<0.001Admission length (days)4 (3--6)4 (4--6)4 (3--7)0.07Ejection fraction\<0.001 - Normal (≥50 %)69.065.676.1 - Moderate (30--49 %)26.831.117.7 - Poor (\<30 %)4.23.36.2Time from admission to PCI (days)0 (0--2)0 (0--2)1 (0--3)\<0.001Discharge diagnosis (%) - UA26.621.837.0\<0.001 - NSTEMI31.230.133.50.28 - STEMI42.248.129.4\<0.001CABG indicates coronary artery bypass grafting; *HF* heart failure; *MI* myocardial infarction; *NSTEMI* non-ST-segment elevation myocardial infarction; *PCI* percutaneous coronary intervention; *STEMI* ST-segment elevation myocardial infarction; *TIA* transient ischaemic attack; and *UA* unstable angina^a^Combination therapy is defined as the collective use of aspirin, thienopyridines, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and statins

Figure [1](#Fig1){ref-type="fig"} depicts the discharge prescription rates and medication use at follow-up in the study cohort according to ACS spectrum. Institutional discharge and follow-up prescription rates are presented in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}, respectively. At discharge, 94.0 % of the overall study patients were prescribed aspirin, 99.8 % thienopyridines, 8.0 % oral anticoagulants, 80.3 % ACE-I/ARBs, 87.1 % β-blockers, and 95.5 % statins. There were marginal numbers of patients discontinuing treatment and being initiated on treatment after discharge (Table [2](#Tab2){ref-type="table"}). Overall, the use of aspirin (*p* = 1.00), ACE-I/ARB (*p* = 0.20), β-blocker (*p* = 0.22), and statin (*p* = 0.50) therapies, as well as the collective use of the 5 guideline-recommended medications (*p* = 0.06), were similar at discharge and 1-month follow-up, whereas the use of thienopyridines declined (*p* = 0.02).Fig. 1Medication use at discharge and 1-month follow-up according to ACS spectrum. \**P* \< 0.05. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker; ACS, acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; and UA, unstable anginaFig. 2Institutional discharge prescription rates. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blockerFig. 3Institutional follow-up prescription rates. ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blockerTable 2Change in medication use during 1-month follow-upPharmacological agentNo. of patients being initiated on therapy during follow-up (%)^a^No. of patients discontinuing therapy during follow-up (%)^b^Aspirin5 (8.3)5 (0.5)Thienopyridine--7 (0.7)ACE-I/ARB5 (2.5)18 (2.2)β-blocker5 (3.9)15 (1.7)Statin5 (11.1)10 (1.0)ACE-I/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker^a^As % of patients who had not been prescribed therapy at discharge^b^As % of patients who had received therapy at discharge

The results of multivariable analysis for the 5-drug combination therapy at discharge are presented in Table [3](#Tab3){ref-type="table"}. The model c-statistic and Hosmer-Lemeshow P-values were 0.69 and 0.67, respectively, indicating good discrimination and calibration.Table 3Independent predictors of 5-drug combination therapy at dischargeParameterAdjusted OR95 % CI*P*Positive predictors - STEMI2.021.43--2.85\<0.001 - Enrolled in interventional centre1.681.26--2.260.001 - Hypercholesterolaemia1.651.20--2.280.002 - Hypertension1.611.19--2.180.002Negative predictors - Unstable angina0.630.44--0.900.01 - Age0.990.97--1.000.02*CI* indicates confidence interval; *OR* odds ratio; and *STEMI* ST-segment elevation myocardial infarction

Discussion {#Sec8}
==========

The present study revealed that 65 % of the PCI-treated ACS patients received all 5 guideline-recommended classes of pharmacological agents at discharge in the first subset of 1000 patients in the ongoing Dutch CCR registry. Individual utilisation rates for aspirin, thienopyridine, ACE-I/ARBs, β-blockers, and statins at hospital discharge were 94 %, 100 %, 80 %, 87 %, and 96 %, respectively, and were similar at 1-month follow-up except for thienopyridines. Importantly, STEMI and UA were the most powerful respective positive and negative predictors of the use of combination therapy at discharge. The present utilisation rates of guideline-recommended pharmacological agents represent current medical discharge management of ACS in our registry/region and serve as a baseline regional core measure performance.

Although randomised controlled trials set the 'gold standard' for evaluating treatment efficacy, observational studies afford unique and valuable insights into treatment effectiveness and generalisability in routine practice \[[@CR10]\]. In this regard, multiple registries have demonstrated the underuse of evidence-based medical therapies at discharge among patients with ACS, irrespective of geographic location \[[@CR11]--[@CR15]\]. In these studies, 16--90 % received aspirin at hospital discharge, 17--70 % thienopyridines, 60--81 % ACE-I/ARBs, 50--90 % β-blockers, and 70--84 % statins. The collective use rates of these pharmacological agents ranged from 46 % to 51 %. The present study indicates that both individual and collective use rates of these agents in ACS patients at discharge were reasonably high in our region compared with aforementioned registries \[[@CR11]--[@CR15]\].

The use of thienopyridines marginally decreased from 99.8 % at discharge to 99.1 % at 1-month follow-up corresponding to a total number of 7 patients discontinuing therapy. Nevertheless, this reached statistical significance (McNemar *p* = 0.02). Although the exact reasons for discontinuing medications during this period are not clear, potential factors, including adverse side effects or patient compliance may constitute barriers to continuation of therapy. Of note, the 7 patients discontinuing thienopyridine therapy received either aspirin or oral anticoagulants during follow-up.

Despite the encouraging utilisation rates of 5-class combination treatment at discharge and follow-up in the present study, there is still room for improvement when considering that all centres should reach the same level as the top 3 (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). However, it is important to note that the absence of one of the 5 classes of pharmacological agents after ACS does not necessarily imply that patients are not treated optimally. Practice guidelines recommend the use of these agents in all patients with ACS, unless contraindicated \[[@CR3], [@CR4], [@CR6]\]. For instance, significant bradycardia (heart rate \<50 beats/min) or hypotension (systolic blood pressure \<90 mmHg) are contraindications to β-blockers. ACE-I are indicated in all patients with STEMI and NSTE-ACS patients with left ventricular ejection fraction ≤40 %, heart failure, diabetes, hypertension, or chronic kidney disease, however, in the absence of severe renal dysfunction (serum creatinine \>221 μmol/l in men or \>177 μmol/l in women) \[[@CR3], [@CR4]\]. Thus, patients receiving a combination of all indicated therapies are optimally treated from a clinical perspective.

Several investigators have studied the determinants of individual medication use after ACS \[[@CR11], [@CR12], [@CR16]--[@CR18]\]. The current report builds on prior work by demonstrating that UA was also independently associated with lower use of combination therapy at discharge, along with the previously reported negative predictor advanced age. In contrast, patients presenting with STEMI, hypertension, hypercholesterolaemia and those enrolled to the registry in an interventional centre were more likely to be given optimal medical treatment.

Recommendations from the European Society of Cardiology guidelines stress the importance of the development of regional and/or national programs to measure performance indicators systematically that can provide feedback to individual hospitals \[[@CR3]\]. In accordance with these recommendations, the Netherlands Society of Cardiology (NVVC) has developed core competencies that recognise the important role of quality improvement for the management of ACS (that is, the 'NVVC! Connect' project). In this regard, the CCR registry serves as an ideal model for implementation and follow-up of measures aimed to improve institutional compliance with national quality standards. Moreover, it exemplifies a collaborative study design that employs a regional PCI registry platform, potentially enhancing hospital care quality in the context of an actively enrolling research study. In response to the current observations, the regional 'NVVC! Connect' committee will launch several initiatives to improve compliance with medical management recommendations from the ESC guidelines. Of note, pre-hospital care \[[@CR19]\], rapid identification and risk stratification \[[@CR20]\] of these patients are particularly relevant to this concept, because these represent equally important core competencies for effective care likely improving secondary prevention after ACS.

The current results provide a baseline measurement for discharge management of ACS in our region, and adherence at 1-month follow-up. Although initiation of evidence-based therapies after discharge is encouraging, numerous studies have documented the rapid decline in adherence to medications after hospitalisation for ACS \[[@CR21], [@CR22]\]. For this reason, we will perform a subsequent measurement at the end of the registry when the intended number of 4000 patients is recruited. Consequently, this will provide essential information regarding patient adherence to evidence-based pharmacological therapies at 1-year follow-up, as previously demonstrated in the Dutch MISSION! study \[[@CR19]\]. On the other hand, we will also compare the current results with data from the following consecutive three subsets of 1000 patients. This will provide an important evaluation of patient management over time and will ascertain whether a quality gap exists in our region. This in turn may lead to new processes that help institutions meet benchmarks of quality care. More importantly, we will examine the relationship between the collective use of these agents and 1-month and 1-year outcome at the end of the registry.

The current study has several limitations that deserve comment. First, we did not collect detailed information on contraindications to medications. However, we assume that patient profiles were evaluated before institution of agents and other reasons for withholding medical therapy were probably uncommon. Second, adherence to medication was assessed at 1-month follow-up. Use rates of pharmacological agents at 1-year follow-up may vary due to discontinuation and initiation of treatment after discharge. We will address this issue at the end of the registry when the 1-year follow-up is complete.

Conclusion {#Sec9}
==========

The present individual and collective utilisation rates of guideline-recommended pharmacological therapies indicate that current discharge management after ACS is of substantial quality in our registry and region. However, despite high rates of use, there is still potential for quality improvement of medical management of these patients. Importantly, the CCR registry will continue to provide essential data concerning regional performance and will potentially enhance hospital care quality in the context of an actively enrolling research study.

Appendix {#Sec10}
========

Participating centres {#Sec11}
---------------------

Albert Schweitzer Hospital, Dordrecht; Beatrix Hospital, Gorinchem; Erasmus MC Rotterdam; Havenziekenhuis, Rotterdam; IJsselland Hospital, Rotterdam; Ikazia Hospital, Rotterdam; Maasstad Hospital, Rotterdam; Ruwaard van Putten Hospital, Spijkenisse; Sint Franciscus Gasthuis, Rotterdam; Van Weel-Bethesda Hospital, Dirksland; and Vlietland Hospital, Schiedam. All centres are in the Netherlands.

Member hospitals are listed in Appendix A.
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